Fluidigm (NASDAQ: FLDM) stock rose 26.62% to $7.8 in the extended-hours session. The company’s stock which focuses on the most urgent requirements, including cancer, immunology, and immunotherapy in translation and clinical study, is currently trading at a distance of -1.01% from its 20-days Simple Moving Average.
What they do…
The company design, generate and sell multi-omic solutions using patented CyTOF and the technology of micro-fluidics to provide practical insight into health and disease, identify biomarkers for decision-making, and speed the production of more effective therapies.
- Top 3 Cybersecurity Stocks You Should Keep on your Watch List
- The Top Cryptocurrency Stocks Flight in the Market for long-term
Most Recent Development
Advanta Dx SARS-CoV-2 RT-PCR testing involves no collection by intrusive nasopharyngeal swab, and 100 percent agreement between Saliva findings from the Advanta Dx Assay and paired Nasopharyngeal samples checked with approved trials was demonstrated in clinical studies for submission.
Several researchers confirm that the accuracy of the COVID-19 saliva-based test is equivalent to the accuracy of the series of nasopharyngeal substances. In a systematic examination and meta-analysis published in JAMA Internal Medicine in January 2021, saliva-based testing is equally responsive and unique. It offers an appealing alternative to invasive nasopharyngeal testing.
We have seen a massive interest in our research technologies since the launch of our saliva-based COVID-19 test solution in the United States. We are delighted to have offered one of the first saliva-based tests to be readily available in Europe, where the overall targeted demand for the testing COVID- 19 based on forecasts from third parties and businesses is from $5 billion to $7 billion, said Chris Linthwaite, Fluidigm President and CEO. The European area records one million infections every four days, and over 27 million cases have been identified since the pandemic started.
Fluidigm performs continuous silicon research to evaluate the efficacy of the Advanta Dx Test method for SARS-CoV-2 identification. To date, none of the viral mutations released had any significant effect on the regions of the viral genome targeted by the primers and samples.
The stock market has frequently been too confusing in the past, catching even experienced traders off guard. Even when results are as expected, the market sometimes swings in the opposite direction. Doubts and speculations often result from such events. It may make sense to keep an eye on the historical performance of stock at such a time. It is also useful to understand both the short and long-term trends of the store. The share price of Fluidigm Corporation (NASDAQ: FLDM) rose 3.18 percent last week but is down -11.24% since the beginning of the quarter. Over the last six months, the stock’s price has fallen by 3.18% but has increased by 2.67% year-to-date.
Meanwhile, 3 brokerages have issued ratings for the stock according to data provided by FactSet Research. 0 analysts recommend it to be sold, while 0 recommend it to be overweight. There has been a buy rating from 3 analysts and a hold rating from 0 other analysts. Based on consensus recommendations, the rating is Buy.